Synthesis and In Vitro Evaluation of Aspartic Acid Based Microgels for Sustained Drug Delivery.

drug loading dynamic swelling microgels percent drug release

Journal

Gels (Basel, Switzerland)
ISSN: 2310-2861
Titre abrégé: Gels
Pays: Switzerland
ID NLM: 101696925

Informations de publication

Date de publication:
24 Dec 2021
Historique:
received: 15 11 2021
revised: 22 12 2021
accepted: 22 12 2021
entrez: 20 1 2022
pubmed: 21 1 2022
medline: 21 1 2022
Statut: epublish

Résumé

The main focus of the current study was to sustain the releasing behavior of theophylline by fabricated polymeric microgels. The free radical polymerization technique was used for the development of aspartic acid-co-poly(2-acrylamido-2-methylpropanesulfonic acid) microgels while using various combinations of aspartic acid, 2-acrylamido-2-methylpropanesulfonic acid, and N',N'-methylene bisacrylamide as a polymer, monomer, and cross-linker, respectively. Ammonium peroxodisulfate and sodium hydrogen sulfite were used as initiators. Characterizations such as DSC, TGA, SEM, FTIR, and PXRD were performed for the fabricated microgels to assess their thermal stability with unreacted polymer and monomer, their surface morphology, the formation of a new polymeric system of microgels by evaluating the cross-linking of functional groups of the microgels' contents, and to analyze the reduction in crystallinity of the theophylline by fabricated microgels. Various studies such as dynamic swelling, drug loading, sol-gel analysis, in vitro drug release studies, and kinetic modeling were carried out for the developed microgels. Both dynamic swelling and percent drug release were found higher at pH 7.4 as compared to pH 1.2 due to the deprotonation of functional groups of aspartic acid and AMPS. Similarly, sol-gel analysis was performed and an increase in gel fraction was observed with the increasing concentration of microgel contents, while sol fraction was decreased. Conclusively, the prepared carrier system has the potential to sustain the release of the theophylline for an extended period of time.

Identifiants

pubmed: 35049547
pii: gels8010012
doi: 10.3390/gels8010012
pmc: PMC8775008
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : National Science Council of Taiwan
ID : MOST 109-2320-B-037-0025
Organisme : National Science Council of Taiwan
ID : 110-2320-B-037-014-MY2
Organisme : Kaohsiung Medical University Research Foundation
ID : KMU-TC109A03-1

Références

Int J Biol Macromol. 2018 Dec;120(Pt B):1624-1631
pubmed: 30287359
Curr Drug Deliv. 2019;16(6):548-564
pubmed: 31577200
Int J Nanomedicine. 2019 Dec 20;14:10035-10046
pubmed: 31908458
Eur J Respir Dis Suppl. 1980;109:54-60
pubmed: 6934088
Carbohydr Polym. 2014 Jan;99:666-78
pubmed: 24274557
Acta Pol Pharm. 2016 Jan-Feb;73(1):175-81
pubmed: 27008812
Colloids Surf B Biointerfaces. 2021 Aug;204:111819
pubmed: 33964528
Carbohydr Polym. 2018 Feb 1;181:1169-1179
pubmed: 29253946
J Sci Food Agric. 2020 Sep;100(12):4425-4432
pubmed: 32388863
BMC Biophys. 2018 Feb 9;11:2
pubmed: 29449937
Int J Biol Macromol. 2019 Feb 1;122:538-548
pubmed: 30389527
Respir Med. 2005 Feb;99(2):135-44
pubmed: 15715180
ISRN Pharm. 2012;2012:763127
pubmed: 22811940
Indian J Pharm Sci. 2015 Jan-Feb;77(1):83-90
pubmed: 25767322
Am J Respir Crit Care Med. 2003 Mar 15;167(6):813-8
pubmed: 12623857
Int J Nanomedicine. 2008;3(2):133-49
pubmed: 18686775
AAPS PharmSciTech. 2020 May 17;21(5):141
pubmed: 32419084
Curr Drug Deliv. 2019;16(3):242-253
pubmed: 30360742
Front Chem. 2020 Feb 04;8:50
pubmed: 32117876
Clin Pharmacokinet. 1978 Jul-Aug;3(4):267-93
pubmed: 354635
Pharmaceuticals (Basel). 2021 Mar 08;14(3):
pubmed: 33800248
J Mater Sci Mater Med. 2008 Jan;19(1):305-10
pubmed: 17597373
J Pharm Sci. 2014 Jan;103(1):227-34
pubmed: 24218151
Molecules. 2021 May 19;26(10):
pubmed: 34069585
Int J Pharm. 2019 Oct 5;569:118557
pubmed: 31377405
Bioresour Technol. 2008 Jan;99(2):444-7
pubmed: 17360178
Int J Pharm. 2019 Feb 10;556:236-245
pubmed: 30553956
Int J Pharm. 2007 Oct 1;343(1-2):79-89
pubmed: 17582714
J Pharm Sci. 1983 Oct;72(10):1189-91
pubmed: 6644570
J Mater Sci Mater Med. 2010 Oct;21(10):2805-16
pubmed: 20686825

Auteurs

Muhammad Suhail (M)

School of Pharmacy, Kaohsiung Medical University, 100 Shih-Chuan 1st Road, Kaohsiung 80708, Taiwan.

An Xie (A)

School of Pharmacy, Kaohsiung Medical University, 100 Shih-Chuan 1st Road, Kaohsiung 80708, Taiwan.

Jia-Yu Liu (JY)

School of Pharmacy, Kaohsiung Medical University, 100 Shih-Chuan 1st Road, Kaohsiung 80708, Taiwan.

Wan-Chu Hsieh (WC)

School of Pharmacy, Kaohsiung Medical University, 100 Shih-Chuan 1st Road, Kaohsiung 80708, Taiwan.

Yu-Wen Lin (YW)

School of Pharmacy, Kaohsiung Medical University, 100 Shih-Chuan 1st Road, Kaohsiung 80708, Taiwan.

Muhammad Usman Minhas (MU)

College of Pharmacy, University of Sargodha, Sargodha 40100, Pakistan.

Pao-Chu Wu (PC)

School of Pharmacy, Kaohsiung Medical University, 100 Shih-Chuan 1st Road, Kaohsiung 80708, Taiwan.
Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan.
Drug Development and Value Creation Research Center, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.

Classifications MeSH